## COVID-Q: validation of the first COVID-19 questionnaire based on patient-rated symptom gravity

Spinato G<sup>1,2</sup>, Fabbris C<sup>1</sup>, Conte F<sup>3</sup>, Menegaldo A<sup>1</sup>, Franz L<sup>1</sup>, Gaudioso P<sup>1</sup>, Cinetto F<sup>4</sup>, Agostini C<sup>4</sup>, Costantini G<sup>3</sup>, Boscolo-Rizzo P<sup>5</sup>

- 1: Department of Neurosciences, Section of Otolaryngology and Regional Centre for Head and Neck Cancer, University of Padova, Treviso, Italy
- 2: Department of Surgery, Oncology and Gastroenterology, Section of Oncology and Immunology, University of Padova, Padova, Italy
- 3: Department of Psychology, University of Milano Bicocca, 20126 Milan, Italy
- 4: Department of Medicine, Clinical Immunology and Hematology, University of Padova, Treviso, Italy
- 5: Section of Otorhinolaryngology, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy

## Corresponding author:

Cristoforo Fabbris MD

Department of Neurosciences, University of Padova, Piazza Ospedale 1, 31100, Treviso, Italy cristoforo.fabbris@gmail.com

## Conflicts of Interest, Source of Funding and Compliance with Ethical Standards

The authors have no conflict of interest, funding or financial relationships. An informed consent has been obtained for any procedure involving the patients described in this article. The manuscript has not been submitted to more than one journal for simultaneous consideration. The manuscript has not been published previously (party or in full). All of the authors have participated in the planning, writing or revising the manuscript.

Table S1 – distribution of comorbidities and risk factors within the sample. For statistical analyses, comorbidities were considered as present or not present.

	Total (prop)	Control (prop)	Cases (prop)	Fisher p
N	460	230	230	
Current/ ex smokers	141 (30.65)	70 (30.43)	71 (30.87)	0.919
Hypertension	93 (20.22)	26 (11.3)	67 (29.13)	0.000
Diabetes	26 (5.65)	5 (2.17)	21 (9.13)	0.001
Cardiovascular diseases	39 (8.48)	13 (5.65)	26 (11.3)	0.030
Cerebrovascular diseases	7 (1.52)	2 (0.87)	5 (2.17)	0.285
Tumors	18 (3.91)	9 (3.91)	9 (3.91)	1.000
COPD	26 (5.65)	16 (6.96)	10 (4.35)	0.313
Renal impairment	11 (2.39)	4 (1.74)	7 (3.04)	0.544
Liver diseases	1 (0.22)	0 (0)	1 (0.43)	0.499

Note. N = number of participants per group. Prop = proportion. COPD = Chronic Obstructive Pulmonary Disease. The number in brackets indicates the proportion of affected individuals in each sample/subsample.

Table S2: comparative statistics of the full and constrained models.

Model	AIC	BIC	logLik	X2	df	p
Asthenia						
1PL	3423.79	3502.29	-1692.90			
2PL	3409.65	3521.19	-1677.82	30.143	8	0.000
Influenza						
1PL	3928.78	4007.27	-1945.39			
2PL	3896.02	4007.56	-1921.01	48.759	8	0.000
Ear/ Nose						
1PL	3014.72	3084.95	-1490.36			
2PL	3017.15	3116.30	-1484.57	11.566	7	0.116
Breathing						
1PL	3887.78	3966.27	-1924.89			
2PL	3797.78	3909.32	-1871.89	105.999	8	0.000
Throat						
1PL	1262.51	1299.69	-622.25			
2PL	1236.65	1286.23	-606.33	31.857	3	0.000

 $\it Note.$  Fit statistics for common-slope (1PL) and unconstrained (2PL) models for each of the 5 components individuated by the PCA.

Table S3. Swab outcome, comorbidities, and clinical manifestations in the enrolled population: descriptive statistics.

	nbr.val	mean	std.dev	range_2
Swab outcome	460	0,500	0,501	0 - 1
Age	460	51,031	15,206	20 - 100
Sex <sup>a</sup>	460	0,378	0,485	0 - 1
Smoking status <sup>b</sup>	458	0,308	0,462	0 - 1
Hypertension <sup>c</sup>	459	0,203	0,402	0 - 1
Diabetes <sup>c</sup>	459	0,057	0,231	0 - 1
Cardiovascular diseases <sup>c</sup>	459	0,085	0,279	0 - 1
Cerebrovascular diseases <sup>c</sup>	459	0,015	0,123	0 - 1
Tumors <sup>c</sup>	458	0,039	0,195	0 - 1
$COPD^{c}$	459	0,057	0,231	0 - 1
Renal Impairment <sup>c</sup>	458	0,024	0,153	0 - 1
Asthenia	460	1,207	2,205	0 - 10
Gastrointestinal symptms	460	0,946	1,552	0 - 8
Fever	460	1,007	1,682	0 - 6
Ear/nose symptoms	460	0,846	1,525	0 - 9
Breathing symptoms	460	1,674	2,356	0 - 11
Throat symptoms	460	0,548	1,168	0 - 7
Anosmia/Ageusia	460	1,213	1,870	0 - 5
Muscle pain	460	0,370	0,675	0 - 2
Total score	460	7,809	9,588	0 - 47
Partial score	460	2,887	3,581	0 - 16

<sup>&</sup>lt;sup>a</sup> Sex was coded as 0 for females and 1 for males.
<sup>b</sup> Smoking status was coded as 0 for never, and 1 for former or current smokers.

<sup>&</sup>lt;sup>c</sup> Hypertension, Diabetes, Cardiovascular and Cerebrovascular diseases, Tumors, Chronic Obstructive Pulmonary Disease (COPD) and Renal impairment were coded as 0 for absent and 1 for present.

*Table S4*. Rare-event logistic regression predicting SARS-CoV-2 – COVID-Q total score used as predictor.

Predictor	b	Exp(b)	S.E.	Z	p
(Intercept)	-4.768	0.008	0.169	-28.178	0.000
Demographics					
Age	0.037	1.038	0.011	3.456	0.001
Sex <sup>a</sup>	1.118	3.057	0.275	4.059	0.000
COVID-19 Symptom questionnaire					
Total score	0.184	1.203	0.019	9.573	0.000
Comorbidities and smoking status					
Smoking status <sup>b</sup>	-0.406	0.666	0.287	-1.414	0.157
Hypertension <sup>c</sup>	0.482	1.620	0.372	1.295	0.195
Diabetes <sup>c</sup>	0.296	1.344	0.698	0.424	0.672
Cardiovascular diseases <sup>c</sup>	0.116	1.123	0.529	0.219	0.827
Cerebrovascular diseases <sup>c</sup>	-1.386	0.250	1.193	-1.162	0.245
Tumors <sup>c</sup>	-0.735	0.479	0.620	-1.186	0.236
COPD <sup>c</sup>	-1.045	0.352	0.656	-1.592	0.111
Renal Impairment <sup>c</sup>	0.097	1.102	1.102	0.088	0.930

Note. COPD = chronic obstructive pulmonary disease

<sup>a</sup> Gender was coded as 0 for females and 1 for males.

<sup>b</sup> Smoking status was coded as 0 for never, and 1 for former or current smokers.

<sup>&</sup>lt;sup>c</sup> Hypertension, Diabetes, Cardiovascular and Cerebrovascular diseases, Tumors, COPD and Renal impairment were coded as 0 for absent and 1 for present.

Table S5. Rare-event logistic regression predicting SARS-CoV-2 infection. COVID-Q's subscale scores used as predictors.

Predictor	b	Exp(b)	S.E.	Z	p
(Intercept)	-3.194	0.041	0.178	-17.989	0.000
Demographics					
Age	0.041	1.041	0.012	3.267	0.001
Sex <sup>a</sup>	1.144	3.140	0.323	3.543	0.000
COVID-Q					
Asthenia	-0.098	0.907	0.109	-0.904	0.366
Gastrointestinal symptoms	0.008	1.008	0.149	0.055	0.956
Fever	0.289	1.334	0.151	1.908	0.056
Ear/nose symptoms	0.086	1.089	0.135	0.636	0.525
Breathing symptoms	0.553	1.738	0.132	4.184	0.000
Throat symptoms	-0.249	0.780	0.187	-1.329	0.184
Anosmia/Ageusia	0.807	2.240	0.124	6.524	0.000
Muscle pain	-0.311	0.733	0.347	-0.896	0.370
Comorbidities and smoking status					
Smoking status <sup>b</sup>	-0.410	0.664	0.335	-1.225	0.221
Hypertension <sup>c</sup>	0.411	1.508	0.423	0.971	0.331
Diabetes <sup>c</sup>	0.438	1.549	0.839	0.522	0.602
Cardiovascular diseases <sup>c</sup>	-0.005	0.995	0.620	-0.007	0.994
Cerebrovascular diseases <sup>c</sup>	-1.597	0.202	1.513	-1.056	0.291
Tumors	-1.152	0.316	0.737	-1.563	0.118
COPD	-1.243	0.288	0.751	-1.655	0.098
Renal Impairment	0.314	1.369	1.328	0.237	0.813

*Note*. COPD = chronic obstructive pulmonary disease

 <sup>&</sup>lt;sup>a</sup> Gender was coded as 0 for females and 1 for males.
 <sup>b</sup> Smoking status was coded as 0 for never, and 1 for former or current smokers.

<sup>&</sup>lt;sup>c</sup> Hypertension, Diabetes, Cardiovascular and Cerebrovascular diseases, Tumors, COPD and Renal impairment were coded as 0 for absent and 1 for present.